A bioavailability study comparing 3 different AZD1981 tablets
Study identifier:D9830C00020
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1981, current small-particle tablet, AZD1981, new small-particle tablet, AZD1981, new large-particle table
Sex
All
Actual Enrollment
16
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Apr 2011
Primary Completion Date: 01 May 2011
Study Completion Date: 01 Jun 2011
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Treatment A | Drug: AZD1981, current small-particle tablet 3x100 mg per oral, single dose in fasted state |
| Experimental: Treatment B | Drug: AZD1981, new small-particle tablet 3x100 mg per oral, single dose |
| Experimental: Treatment C | Drug: AZD1981, new small-particle tablet 3x100 mg per oral, single dose |
| Experimental: Treatment D | Drug: AZD1981, new large-particle table 3x100 mg per oral, single dose in fasted state |
Contacts
Investigators
Principal Investigator
Wolfgang Kühn
Quintiles AB, Phase 1 Services
